Botulinum toxin type A for cephalic cutaneous allodynia in chronic migraine: a randomized, double-blinded, placebo-controlled trial

Detalhes bibliográficos
Autor(a) principal: Hollanda, Luciano
Data de Publicação: 2014
Outros Autores: Monteiro, Larissa, Melo, Ailton de Souza
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFBA
Texto Completo: http://repositorio.ufba.br/ri/handle/ri/17187
Resumo: Texto completo: acesso restrito. p.70-73
id UFBA-2_f0b6b5ae7cfab3132885f2cedaa53124
oai_identifier_str oai:repositorio.ufba.br:ri/17187
network_acronym_str UFBA-2
network_name_str Repositório Institucional da UFBA
repository_id_str 1932
spelling Hollanda, LucianoMonteiro, LarissaMelo, Ailton de SouzaHollanda, LucianoMonteiro, LarissaMelo, Ailton de Souza2015-03-19T15:04:36Z20142035-8385http://repositorio.ufba.br/ri/handle/ri/17187v. 6, n. 4Texto completo: acesso restrito. p.70-73Cephalic allodynia (CA) can be observed in 50-70% of patients with chronic migraine (CM). The aim of this trial was to assess the efficacy of botulinum toxin type A (Botx-A) in the treatment of CA associated with CM. In this placebo-controlled trial, patients were randomized either into Botx-A or 0.9% saline injections and efficacy measures were assessed every 4 weeks for 3 months. Efficacy endpoints were number of migraine episodes associated with CA, changes from baseline in visual analogical scale scores for pain (VAS) and frequency of common analgesics use for migraine. A total of 38 subjects were randomized to saline (n=18) or Botx-A (n=20). There were no significant differences in baseline between active intervention or placebo groups regarding mean age, number of headache episodes [mean 12.1 (9.22) and 17.00 (9.69) respectively; P=0.12], pain severity as measured by the VAS or frequency of analgesic use for headache episodes. Efficacy analysis showed that Botx-A injections led to an important decrease from baseline in the mean migraine episodes associated with CA after 12 weeks (5.20 versus 11.17; P=0.01). Also, VAS scores and frequency of analgesics use for headache were significantly reduced in the Botx-A group. This study suggests that Botx-A injections are superior to saline in the treatment of CA associated with CM, with mild self limited side effects.Submitted by Edileide Reis (leyde-landy@hotmail.com) on 2015-03-18T15:48:56Z No. of bitstreams: 1 Luciano Hollanda.pdf: 644979 bytes, checksum: 299f86c2734101543b25e8ce1e69c38d (MD5)Approved for entry into archive by Delba Rosa (delba@ufba.br) on 2015-03-19T15:04:36Z (GMT) No. of bitstreams: 1 Luciano Hollanda.pdf: 644979 bytes, checksum: 299f86c2734101543b25e8ce1e69c38d (MD5)Made available in DSpace on 2015-03-19T15:04:36Z (GMT). No. of bitstreams: 1 Luciano Hollanda.pdf: 644979 bytes, checksum: 299f86c2734101543b25e8ce1e69c38d (MD5) Previous issue date: 2014http://dx.doi.org/10.4081/ni.2014.5133reponame:Repositório Institucional da UFBAinstname:Universidade Federal da Bahia (UFBA)instacron:UFBAMigraineRandomized controlled trialAllodyniaBotulinum toxinAdverse eventBotulinum toxin type A for cephalic cutaneous allodynia in chronic migraine: a randomized, double-blinded, placebo-controlled trialNeurology Internationalinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article10000-01-01info:eu-repo/semantics/openAccessengORIGINALLuciano Hollanda.pdfLuciano Hollanda.pdfapplication/pdf644979https://repositorio.ufba.br/bitstream/ri/17187/1/Luciano%20Hollanda.pdf299f86c2734101543b25e8ce1e69c38dMD51LICENSElicense.txtlicense.txttext/plain1345https://repositorio.ufba.br/bitstream/ri/17187/2/license.txtff6eaa8b858ea317fded99f125f5fcd0MD52TEXTLuciano Hollanda.pdf.txtLuciano Hollanda.pdf.txtExtracted texttext/plain25549https://repositorio.ufba.br/bitstream/ri/17187/3/Luciano%20Hollanda.pdf.txt853fe6b868f2c626139a81aca9d9f8f1MD53ri/171872022-08-08 13:18:15.8oai:repositorio.ufba.br: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Repositório InstitucionalPUBhttp://192.188.11.11:8080/oai/requestopendoar:19322022-08-08T16:18:15Repositório Institucional da UFBA - Universidade Federal da Bahia (UFBA)false
dc.title.pt_BR.fl_str_mv Botulinum toxin type A for cephalic cutaneous allodynia in chronic migraine: a randomized, double-blinded, placebo-controlled trial
dc.title.alternative.pt_BR.fl_str_mv Neurology International
title Botulinum toxin type A for cephalic cutaneous allodynia in chronic migraine: a randomized, double-blinded, placebo-controlled trial
spellingShingle Botulinum toxin type A for cephalic cutaneous allodynia in chronic migraine: a randomized, double-blinded, placebo-controlled trial
Hollanda, Luciano
Migraine
Randomized controlled trial
Allodynia
Botulinum toxin
Adverse event
title_short Botulinum toxin type A for cephalic cutaneous allodynia in chronic migraine: a randomized, double-blinded, placebo-controlled trial
title_full Botulinum toxin type A for cephalic cutaneous allodynia in chronic migraine: a randomized, double-blinded, placebo-controlled trial
title_fullStr Botulinum toxin type A for cephalic cutaneous allodynia in chronic migraine: a randomized, double-blinded, placebo-controlled trial
title_full_unstemmed Botulinum toxin type A for cephalic cutaneous allodynia in chronic migraine: a randomized, double-blinded, placebo-controlled trial
title_sort Botulinum toxin type A for cephalic cutaneous allodynia in chronic migraine: a randomized, double-blinded, placebo-controlled trial
author Hollanda, Luciano
author_facet Hollanda, Luciano
Monteiro, Larissa
Melo, Ailton de Souza
author_role author
author2 Monteiro, Larissa
Melo, Ailton de Souza
author2_role author
author
dc.contributor.author.fl_str_mv Hollanda, Luciano
Monteiro, Larissa
Melo, Ailton de Souza
Hollanda, Luciano
Monteiro, Larissa
Melo, Ailton de Souza
dc.subject.por.fl_str_mv Migraine
Randomized controlled trial
Allodynia
Botulinum toxin
Adverse event
topic Migraine
Randomized controlled trial
Allodynia
Botulinum toxin
Adverse event
description Texto completo: acesso restrito. p.70-73
publishDate 2014
dc.date.issued.fl_str_mv 2014
dc.date.accessioned.fl_str_mv 2015-03-19T15:04:36Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://repositorio.ufba.br/ri/handle/ri/17187
dc.identifier.issn.none.fl_str_mv 2035-8385
dc.identifier.number.pt_BR.fl_str_mv v. 6, n. 4
identifier_str_mv 2035-8385
v. 6, n. 4
url http://repositorio.ufba.br/ri/handle/ri/17187
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.pt_BR.fl_str_mv http://dx.doi.org/10.4081/ni.2014.5133
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFBA
instname:Universidade Federal da Bahia (UFBA)
instacron:UFBA
instname_str Universidade Federal da Bahia (UFBA)
instacron_str UFBA
institution UFBA
reponame_str Repositório Institucional da UFBA
collection Repositório Institucional da UFBA
bitstream.url.fl_str_mv https://repositorio.ufba.br/bitstream/ri/17187/1/Luciano%20Hollanda.pdf
https://repositorio.ufba.br/bitstream/ri/17187/2/license.txt
https://repositorio.ufba.br/bitstream/ri/17187/3/Luciano%20Hollanda.pdf.txt
bitstream.checksum.fl_str_mv 299f86c2734101543b25e8ce1e69c38d
ff6eaa8b858ea317fded99f125f5fcd0
853fe6b868f2c626139a81aca9d9f8f1
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFBA - Universidade Federal da Bahia (UFBA)
repository.mail.fl_str_mv
_version_ 1808459494841122816

Registros relacionados